SciVision Biotech Inc.

TWSE:1786 Lagerbericht

Marktkapitalisierung: NT$9.3b

SciVision Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

SciVision Biotech wird voraussichtlich ein Umsatzwachstum verzeichnen 35.6% p.a. sinken.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum21.2%
Wachstumsrate der Einnahmen37.3%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert18 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

Aug 30
SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's

Jul 22
SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's

SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

Jun 28
SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

Jun 14
SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly

Jun 04
SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly

Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

Apr 01
Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Apr 20
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Apr 02
SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Mar 15
Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Feb 25
Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Feb 05
Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Jan 18
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

Jan 01
Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

Dec 14
SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Nov 25
Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Gewinn- und Umsatzwachstumsprognosen

TWSE:1786 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (TWD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20251,431N/AN/A5551
12/31/20241,036N/AN/A4941
6/30/2024815213283299N/A
3/31/2024788197291305N/A
12/31/2023713178257272N/A
9/30/2023670168202223N/A
6/30/2023628159192212N/A
3/31/2023577148151169N/A
12/31/2022557142167182N/A
9/30/2022538138151162N/A
6/30/20225001128497N/A
3/31/2022495104116129N/A
12/31/20215061027399N/A
9/30/202149711298159N/A
6/30/202149112665129N/A
3/31/202146811658127N/A
12/31/202046712860126N/A
9/30/202046513383122N/A
6/30/202044712485189N/A
3/31/202044312730171N/A
12/31/20194381212204N/A
9/30/2019410112-109140N/A
6/30/2019380103-76120N/A
3/31/201933081-6099N/A
12/31/20183308716112N/A
9/30/201831473-8111N/A
6/30/201829658-49101N/A
3/31/201831455N/A109N/A
12/31/201725817N/A16N/A
9/30/201724421N/A26N/A
6/30/2017251-28N/A-19N/A
3/31/2017231-28N/A-50N/A
12/31/2016228-26N/A38N/A
9/30/2016218-37N/A37N/A
6/30/201623836N/A95N/A
3/31/201625041N/A107N/A
12/31/201526555N/A50N/A
9/30/201523722N/A33N/A
6/30/2015197-5N/A11N/A
3/31/2015181-9N/A17N/A
12/31/2014158-22N/A2N/A
9/30/20141756N/A19N/A
6/30/201418826N/A2N/A
3/31/201419434N/A15N/A
12/31/201320140N/A37N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von 1786 über der Sparquote liegt (1%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von 1786 schneller wachsen werden als der Markt TW

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 1786 in den nächsten 3 Jahren signifikant steigen werden.

Einnahmen vs. Markt: 1786Die Einnahmen des Unternehmens (35.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt TW (10.7% pro Jahr).

Hohe Wachstumseinnahmen: 1786Die Einnahmen des Unternehmens (35.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 1786 in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y